ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
ACAD
36.32
+0.49
+1.37%
AEMD
0.967
-0.013
-1.2857%
APRI
1.81
-0.01
-0.55%
ARNA
27.29
-0.02
-0.07%
ATEC
4.18
+0.06
+1.46%
CNAT
5.104
+0.094
+1.8802%
CRXM
0.137
+0.034
+32.9767%
CYTX
0.485
+0.02
+4.301%
DXCM
44.9
-0.08
-0.18%
GNMK
7.86
+0.02
+0.26%
HALO
17.84
+0.07
+0.39%
ILMN
209.63
+4.45
+2.17%
INNV
0.087
0.00
0.00%
INO
6.3
+0.05
+0.80%
ISCO
1.65
+0.11
+7.14%
ISIS
57.56
0.00
0.00%
LGND
144.7
+1.35
+0.94%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
-0.03
-4.03%
MEIP
2.63
+0.01
+0.38%
MNOV
6.15
-0.04
-0.65%
MRTX
15.832
+0.282
+1.8109%
MSTX
0.13
-0.01
0.00%
NBIX
59.406
+0.446
+0.756%
NUVA
55.32
+0.75
+1.37%
ONCS
1.26
-0.03
-2.33%
ONVO
1.629
+0.229
+16.3857%
OREX
1.79
-0.03
-1.65%
OTIC
3.425
-0.05
-1.439%
QDEL
41.65
-0.3
-0.72%
RCPT
231.96
0.00
0.00%
RGLS
1.22
-0.03
-2.40%
RMD
79.29
+0.5
+0.63%
SCIE
0
0.00
0.00%
SPHS
2.321
+0.081
+3.616%
SRNE
2.73
+0.23
+9.20%
TROV
0.807
-0.002
-0.2472%
VICL
2.34
-0.04
-1.68%
VOLC
18
0.00
0.00%
ZGNX
40
+0.35
+0.88%
Home » Archive by Category

Xconomy

Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal

September 14, 2017 – 2:55 am

Halozyme Therapeutics has turned a method of delivering a drug more conveniently into partnerships with several large pharmaceutical companies that want to see their infusible drugs delivered via…

[[Click headline to continue reading.]]

Xconomy Award Finalists in the Eye of the National Drug Price Debate

September 13, 2017 – 4:00 am

[Corrected 12:20pm ET; see below.] The national debate over the high cost of healthcare, with prescription drugs at the center, resonates from the chambers of Congress to every American’s…

[[Click headline to continue reading.]]

The Winners of the Xconomy Lifetime Achievement Award Are…

September 12, 2017 – 9:53 am

The editors at Xconomy have been working hard the last few weeks putting together the program for the Xconomy Awards Gala. We are really excited to announce the two winners of the Xconomy Lifetime…

[[Click headline to continue reading.]]

Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More

September 8, 2017 – 3:48 am

The summer doldrums are over. Biotech news came at a breakneck pace this week both before and after Labor Day, starting with the surprise resignation of Novartis’s top executive just days after the…

[[Click headline to continue reading.]]

Levin, Holtzman, 183 Other Bio Leaders Urge White House to Preserve DACA

September 7, 2017 – 12:00 pm

Biotech CEOs Jeremy Levin and Steve Holtzman are continuing their recent push to spur the life sciences industry to speak out against government policies it doesn’t agree with. Levin, CEO of Ovid…

[[Click headline to continue reading.]]

Lasker Award Goes to HPV Vaccine Developers Lowy, Schiller

September 6, 2017 – 7:22 am

A top prize in American biomedical science was awarded today to two scientists for their discoveries that led to the development of a human papillomavirus (HPV) vaccine, which prevents cervical…

[[Click headline to continue reading.]]

Presage Bio Licenses Anti-Cancer Drug to San Diego’s MEI Pharma

September 5, 2017 – 3:20 pm

San Diego’s MEI Pharma (NASDAQ: MEIP) has agreed to pay $2.9 million upfront to Seattle-based Presage Biosciences for exclusive worldwide rights for the anti-cancer drug candidate voruciclib,…

[[Click headline to continue reading.]]

Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More

September 1, 2017 – 2:20 am

[Corrected 9/5/17, 12:22 p.m. See below.] The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight…

[[Click headline to continue reading.]]

Novartis: CAR-T Results In One Month, Or No Charge. Why One Month?

August 31, 2017 – 8:22 am

Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it…

[[Click headline to continue reading.]]

Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000

August 30, 2017 – 10:47 am

Ahead of schedule, Novartis has received the first-ever approval of a genetically modified living cell therapy called CAR-T, which uses a cancer patient’s own immune cells as the medicine….

[[Click headline to continue reading.]]